Human T lymphotropic virus type-1 p30II alters cellular gene expression to selectively enhance signaling pathways that activate T lymphocytes

Retrovirology

Volumn 1, Issue , 2004, Pages

  Michael, Bindhu ^a,d   Nair, Amrithraj M ^a,d   Hiraragi, Hajime ^a   Shen, Lei ^a   Feuer, Gerold ^b   Boris Lawrie, Kathleen ^a,c   Lairmore, Michael D ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; PROTEIN P300;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; NONHUMAN; PROTEIN FUNCTION; PROVIRUS; REGULATOR GENE; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

EID: 18144386244     PISSN: 17424690     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-1-39     Document Type: Article

References (59)

1. Bangham CR: Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control. Int J Hematol 2003, 78: 297-303.
2. Hollsberg P: Mechanisms of T-cell activation by human T-cell lymphotropic virus type I. Microbiol Mol Biol Rev 1999, 63:308-333.
3. Pise-Masison CA, Radonovich M, Mahieux R, Chatterjee P, Whiteford C, Duvall J, Guillerm C, Gessain A, Brady JN: Transcription profile of cells infected with human T-cell leukemia virus type I compared with activated lymphocytes. Cancer Res 2002, 62: 3562-3571.
4. Franchini G: Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood 1995, 86: 3619-3639.
5. Heger P, Rosorius O, Hauber J, Stauber RH: Titration of cellular export factors, but not heteromultimerization, is the molecular mechanism of trans- dominant HTLV-1 Rex mutants. Oncogene 1999, 18:4080-4090.
6. Azran I, Schavinsky-Khrapunsky Y, Aboud M: Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology 2004, 1:20.
7. Albrecht B, Lairmore MD: Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol Rev 2002, 66:396-406.
8. Michael B, Nair A, Lairmore MD: Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression. Front Biosci 2004, 9:2556-2576.
9. Koralnik IJ, Gessain A, Klotman ME, Lo MA, Berneman ZN, Franchini G: Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type I. Proc Natl Acad Sci U S A 1992, 89:8813-8817.
10. Cereseto A, Berneman Z, Koralnik I, Vaughn J, Franchini G, Klotman ME: Differential expression of alternatively spliced pX mRNAs in HTLV-I-infected cell lines. Leukemia 1997, 11:866-870.
11. Chen YMA, Chen SH, Fu CY, Chen JY, Osame M: Antibody reactivities to tumor-suppressor protein p53 and HTLV-I Tof Rex and Tax in HTLV-I-infected people with differing clinical status. Int J Cancer 1997, 71:196-202.
12. Dekaban GA, Peters AA, Mulloy JC, Johnson JM, Trovato R, Rivadeneira E, Franchini G: The HTLV-I orfI protein is recognized by serum antibodies from naturally infected humans and experimentally infected rabbits. Virology 2000, 274:86-93.
13. Pique C, Uretavidal A, Gessain A, Chancerel B, Gout O, Tamouza R, Agis F, Dokhelar MC: Evidence for the chronic in vivo production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides. J Exp Med 2000, 191:567-572.
14. Silverman LR, Phipps AJ, Montgomery A, Ratner L, Lairmore MD: Human T-cell lymphotropic virus type 1 open reading frame II-encoded p30II is required for in vivo replication: evidence of in vivo reversion. J Virol 2004, 78:3837-3845.
15. Bartoe JT, Albrecht B, Collins ND, Robek MD, Ratner L, Green PL, Lairmore MD: Functional role of pX open reading frame II of human T- lymphotropic virus type 1 in maintenance of viral loads in vivo. J Virol 2000, 74:1094-1100.
16. Collins ND, Newbound GC, Albrecht B, Beard JL, Ratner L, Lairmore MD: Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo. Blood 1998, 91:4701-4707.
17. Koralnik IJ, Fullen J, Franchini G: The p12I, p13II, and p30II proteins encoded by human T-cell leukemia/lymphotropic virus type I open reading frames I and II are localized in three different cellular compartments. J Virol 1993, 67:2360-2366.
18. Zhang W, Nisbet JW, Bartoe JT, Ding W, Lairmore MD: Human T-lymphotropic virus type 1 p30(II) functions as a transcription factor and differentially modulates CREB-responsive promoters. J Virol 2000, 74:11270-11277.
19. D'Agostino DM, Ciminale V, Zotti L, Rosato A, Chieco-Bianchi L: The human T-cell lymphotropic virus type 1 Tof protein contains a bipartite nuclear localization signal that is able to functionally replace the amino-terminal domain of Rex. J Virol 1997, 71: 75-83.
20. Ciminale V, Pavlakis GN, Derse D, Cunningham CP, Felber BK: Complex splicing in the human T-cell leukemia virus (HTLV) family of retroviruses: Novel mRNAs and proteins produced by HTLV type I. J Virol 1992, 66:1737-1745.
21. Zhang W, Nisbet JW, Albrecht B, Ding W, Kashanchi F, Bartoe JT, Lairmore MD: Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300. J Virol 2001, 75:9885-9895.
22. Nicot C, Dundr M, Johnson JM, Fullen JR, Alonzo N, Fukumoto R, Princler GL, Derse D, Misteli T, Franchini G: HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat Med 2004, 10:197-201.
23. Younis I, Khair L, Dundr M, Lairmore MD, Franchini G, Green PL: Repression of Human T-Cell Leukemia Virus Type 1 and Type 2 Replication by a Viral mRNA-Encoded Posttranscriptional Regulator. J Virol 2004, 78:11077-11083.
24. Harhaj EW, Good LF, Xiao GT, Sun SC: Gene expression profiles in HTLV-I-immortalized T cells: deregulated expression of genes involved in apoptosis regulation. Oncogene 1999, 18: 1341-1349.
25. de La FC, Deng L, Santiago F, Arce L, Wang L, Kashanchi F: Gene expression array of HTLV type 1-infected T cells: Up-regulation of transcription factors and cell cycle genes. AIDS Res Hum Retroviruses 2000, 16:1695-1700.
26. Kohno T, Moriuchi R, Katamine S, Yamada Y, Tomonaga M, Matsuyama T: Identification of genes associated with the progression of adult T cell leukemia (ATL). Jpn J Cancer Res 2000, 91: 1103-1110.
27. Ng PW, Iha H, Iwanaga Y, Bittner M, Chen Y, Jiang Y, Gooden G, Trent JM, Meltzer P, Jeang KT, Zeichner SL: Genome-wide expression changes induced by HTLV-1 Tax: evidence for MLK- 3 mixed lineage kinase involvement in Tax-mediated NF-kappaB activation. Oncogene 2001, 20:4484-4496.
28. Li C, Wong WH: Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001, 98:31-36.
29. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25: 25-29.
30. Konikova E, Kusenda J: Altered expression of p53 and MDM2 proteins in hematological malignancies. Neoplasma 2003, 50: 31-40.
31. McCoy MA, Gesell JJ, Senior MM, Wyss DF: Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation. Proc Natl Acad Sci U S A 2003, 100:1645-1648.
32. Vaudin P, Delanoue R, Davidson I, Silber J, Zider A: TONDU (TDU), a novel human protein related to the product of vestigial (vg) gene of Drosophila melanogaster interacts with vertebrate TEF factors and substitutes for Vg function in wing formation. Development 1999, 126:4807-4816.
33. Tommerup N, Vissing H: Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders. Genomics 1995, 27: 259-264.
34. Takeshita A, Cardona GR, Koibuchi N, Suen CS, Chin WW: TRAM-1, A novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J Biol Chem 1997, 272:27629-27634.
35. Ju YT, Chang AC, She BR, Tsaur ML, Hwang HM, Chao CC, Cohen SN, Lin-Chao S: gas7: A gene expressed preferentially in growth-arrested fibroblasts and terminally differentiated Purkinje neurons affects neurite formation. Proc Natl Acad Sci U S A 1998, 95:11423-11428.
36. Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, Collins C, Gray JW, Diebold J, Demetrick DJ, Lee JM: Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 2002, 31:301-305.
37. Bour-Jordan H, Blueston JA: CD28 function: a balance of costimulatory and regulatory signals. J Clin Immunol 2002, 22:1-7.
38. Nemorin JG, Duplay P: Evidence that Llck-mediated phosphorylation of p56dok and p62dok may play a role in CD2 signaling. J Biol Chem 2000, 275:14590-14597.
39. Hurd C, Rozengurt E: Uncoupling of protein kinase D from suppression of EGF-dependent c-Jun phosphorylation in cancer cells. Biochem Biophys Res Commun 2003, 302:800-804.
40. Van Lint J, Rykx A, Maeda Y, Vantus T, Sturany S, Malhotra V, Vandenheede JR, Seufferlein T: Protein kinase D: an intracellular traffic regulator on the move. Trends Cell Biol 2002, 12: 193-200.
41. Sun SC, Harhaj EW, Xiao G, Good L: Activation of I-kappaB kinase by the HTLV type 1 tax protein: mechanistic insights into the adaptor function of IKKgamma. AIDS Res Hum Retroviruses 2000, 16:1591-1596.
42. Arnold R, Liou J, Drexler HC, Weiss A, Kiefer F: Caspase-mediated cleavage of hematopoietic progenitor kinase 1 (HPK1) converts an activator of NFkappaB into an inhibitor of NFkappaB. J Biol Chem 2001, 276:14675-14684.
43. Murphy D: Gene expression studies using microarrays: principles, problems, and prospects. Adv Physiol Educ 2002, 26:256-270.
44. Mamane Y, Grandvaux N, Hernandez E, Sharma S, Innocente SA, Lee JM, Azimi N, Lin R, Hiscott J: Repression of IRF-4 target genes in human T cell leukemia virus-1 infection. Oncogene 2002, 21: 6751-6765.
45. Princler GL, Julias JG, Hughes SH, Derse D: Roles of viral and cellular proteins in the expression of alternatively spliced HTLV-1 pX mRNAs. Virology 2003, 317:136-145.
46. Yoshida H, Nishina H, Takimoto H, Marengere LE, Wakeham AC, Bouchard D, Kong YY, Ohteki T, Shahinian A, Bachmann M, Ohashi PS, Penninger JM, Crabtree GR, Mak TW: The transcription factor NF-ATc1 regulates lymphocyte proliferation and Th2 cytokine production. Immunity 1998, 8:115-124.
47. Fujii M, Iwai K, Oie M, Fukushi M, Yamamoto N, Kannagi M, Mori N: Activation of oncogenic transcription factor AP-1 in T cells infected with human T cell leukemia virus type 1. AIDS Res Hum Retroviruses 2000, 16:1603-1606.
48. Mori N, Ueda A, Ikeda S, Yamasaki Y, Yamada Y, Tomonaga M, Morikawa S, Geleziunas R, Yoshimura T, Yamamoto N: Human T-cell leukemia virus type I tax activates transcription of the human monocyte chemoattractant protein-1 gene through two nuclear factor-kappaB sites. Cancer Res 2000, 60:4939-4945.
49. Albrecht B, D'Souza CD, Ding W, Tridandapani S, Coggeshall KM, Lairmore MD: Activation of nuclear factor of activated T cells by human T- lymphotropic virus type 1 accessory protein p12(I). J Virol 2002, 76:3493-3501.
50. Iwai K, Mori N, Oie M, Yamamoto N, Fujii M: Human T-Cell Leukemia Virus Type 1 Tax Protein Activates Transcription through AP-1 Site by Inducing DNA Binding Activity in T Cells. Virology 2001, 279:38-46.
51. Bannister AJ, Kouzarides T: The CBP co-activator is a histone acetyltransferase. Nature 1996, 384:641-643.
52. Garcia-Rodriguez C, Rao A: Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein (CBP). J Exp Med 1998, 187: 2031-2036.
53. Lahti AL, Manninen A, Saksela K: Regulation of T cell activation by HIV-1 accessory proteins: Vpr acts via distinct mechanisms to cooperate with Nef in NFAT-directed gene expression and to promote transactivation by CREB. Virology 2003, 310:190-196.
54. Kehn K, Deng L, de La FC, Strouss K, Wu K, Maddukuri A, Baylor S, Rufner R, Pumfery A, Bottazzi ME, Kashanchi F: The role of cyclin D2 and p21/waf1 in human T-cell leukemia virus type 1 infected cells. Retrovirology 2004, 1:6.
55. Ohta M, Nagai H, Nyunoya H, Shimotohno K: Src-homology domain 2 is responsible for transcriptional suppression induced by expression of Lck. Oncogene 1996, 12:989-997.
56. Li C, Lusis AJ, Sparkes R, Tran SM, Gaynor R: Characterization and chromosomal mapping of the gene encoding the cellular DNA binding protein HTLF. Genomics 1992, 13: 658-664.
57. Wrzesinski S, Seguin R, Liu Y, Domville S, Planelles V, Massa P, Barker E, Antel J, Feuer G: HTLV type 1 Tax transduction in microglial cells and astrocytes by lentiviral vectors. AIDS Res Hum Retroviruses 2000, 16:1771-1776.
58. Kimata JT, Wong F, Wang J, Ratner L: Construction and characterization of infectious human T-cell leukemia virus type 1 molecular clones. Virology 1994, 204:656-664.
59. Ding W, Kim SJ, Nair AM, Michael B, Boris-Lawrie K, Tripp A, Feuer G, Lairmore MD: Human T-Cell Lymphotropic Virus Type 1 p12(I) Enhances Interleukin-2 Production during T-Cell Activation. J Virol 2003, 77:11027-11039.